Account
Watchlists
Bookmarks
Pricing
Market Cap
₹ 4,12,494 Cr
P/E
35.72
Bearish
2
Neutral
5
Bullish
7
Bearish
23
Neutral
5
Bullish
18
Bearish
21
Neutral
0
Bullish
11
No. of Analysts
1Y Price Target
Q3 EPS Estimate
Q3 Revenue Estimate
Price, EPS and Revenue Projections
Strong Buy
14
Buy
20
Hold
2
Sell
3
Strong Sell
1
updated on
Dec 18, 2025
Get In-depth insights on EPS and Revenue forecasts
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Sun Pharmaceutical Industries Limited is a leading global specialty generic company with operations across more than 100 countries. It manufactures a wide range of pharmaceutical formulations covering chronic and acute therapies.
The company's Innovative Medicines segment is experiencing rapid growth, with products addressing dermatology, ophthalmology, and oncology. This division now constitutes about 20% of sales, up from 7.3% seven years ago.
Sun Pharma leads the Indian pharmaceutical market with an 8.3% share, offering a broad range of branded and generic medicines across various therapeutic areas.
Recent acquisitions of Concert Pharmaceuticals and Checkpoint Therapeutics have strengthened Sun Pharma's biopharmaceutical portfolio, particularly in oncology and dermatology.
Environmental sustainability is a focus, with significant efforts in reducing emissions, energy sourcing from renewables, and water conservation, contributing to its ESG performance.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
4,12,494 Cr
Low Risk
35.7
27.5
3.5
5.3
1,910.00
1,547.25
Sales CAGR
1Y
8.42%
3Y
13.86%
5Y
12.92%
10Y
12.67%
Profit CAGR
1Y
13.80%
3Y
—
5Y
5.93%
10Y
—
ROE
TTM
14.84%
3Y
14.57%
5Y
11.74%
10Y
10.76%
ROCE
TTM
18.86%
3Y
17.17%
5Y
13.81%
10Y
13.51%
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Performance
STEADY PERFORMER
Valuation
OVERVALUED
Growth
STABLE
Profitability
MODERATE MARGIN
Technicals
Bearish
Risk
LOW RISK
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1719.20 | 4,12,494 Cr | 35.72 | 5.30 | 0.93 | 14.84 | 18.86 | 10.14 | |
1503.00 | 1,21,574 Cr | 22.34 | 3.69 | 1.06 | 16.53 | 21.05 | 13.58 | |
1269.05 | 1,05,919 Cr | 18.35 | 2.94 | 0.63 | 16.03 | 18.66 | 10.55 | |
2101.00 | 96,519 Cr | 22.32 | 4.92 | 0.57 | 22.03 | 21.92 | 12.98 | |
911.95 | 91,718 Cr | 18.22 | 3.62 | 1.21 | 19.44 | 19.08 | 10.60 | |
2193.70 | 90,491 Cr | 51.75 | 5.92 | 0.00 | 11.45 | 12.34 | 6.16 | |
1205.95 | 70,042 Cr | 20.46 | 2.00 | 0.00 | 9.77 | 12.69 | 6.51 |
Turned 1 L into 2.91 L in last 5 Years
Investor Presentation
1 day ago
Sun Pharma Investor Presentation December 2025
Sun Pharmaceutical Industries Limited has released an investor presentation detailing key aspects of its business and future strategies.
Regulatory Filing
4 days ago
Sun Pharma Newspaper Publication Announcement
Sun Pharmaceutical Industries Limited has published a newspaper advertisement regarding the opening of a Special Window for re-lodgement of transfer deeds as per SEBI guidelines.
